Lars Björnebo

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;116(9):1459-1465
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists
Bjornebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordstrom T; Eklund M; Lundon D; Gronberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e623
PD29-12 THE IMPACT OF THE TIME ELAPSED BETWEEN PRIMARY TREATMENT AND BCR ON CANCER SPECIFIC MORTALITY IN PATIENTS WHO EXPERIENCED BCR AFTER PRIMARY TREATMENT
Pellegrino F; Falagario UG; Abbadi A; Björnebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e1213
PD57-12 PSA RESPONSE AFTER RADIOTHERAPY. IS THERE A DEFINITION OF PSA PERSISTENCE AFTER RT?
Falagario UG; Pellegrino F; Abbadi A; Björnebo L; Valdman A; Carrieri GG; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Wiklund P; Lantz A
Article: JAMA NETWORK OPEN. 2024;7(4):e247131
Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial
Bjornebo L; Discacciati A; Falagario U; Vigneswaran HT; Jaderling F; Gronberg H; Eklund M; Nordstrom T; Lantz A
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;62:61-67
Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer
Arvendell M; Bjornebo L; Eklund M; Falagario UG; Engel JC; Akre O; Gronberg H; Nordstrom T; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1598
Can we reduce unnecessary prostate biopsies in patients with PI-RADS 3 lesions? Role of PSA density and the Stockholm 3 test
Abbadi A; Eklund M; Lantz A; Discacciati A; Engel CJ; Bjornebo L; Falagario UG; Gronberg H; Nordstrom T
Journal article: EUROPEAN UROLOGY. 2024;85:s1534-s1535
The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment
Pellegrino F; Falagario UG; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2024;85:s348
Pre-diagnostic prostate-specific antigen testing and clinical characteristics in men deceased from prostate cancer
Arvendell M; Bjornebo L; Eklund M; Falagario GU; Akre O; Gronberg H; Nordstrom T; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1402-s1403
PSA response after radiotherapy. Is there a definition of PSA persistence after RT?
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Wiklund P; Lantz A
Article: WORLD JOURNAL OF UROLOGY. 2023;41(11):2967-2974
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
Falagario UG; Lantz A; Jambor I; Busetto GM; Bettocchi C; Finati M; Ricapito A; Luzzago S; Ferro M; Musi G; Totaro A; Racioppi M; Carbonara U; Checcucci E; Manfredi M; D'Aietti D; Porcaro AB; Nordstrom T; Bjornebo L; Oderda M; Soria F; Taimen P; Aronen HJ; Perez IM; Ettala O; Marchioni M; Simone G; Ferriero M; Brassetti A; Napolitano L; Carmignani L; Signorini C; Conti A; Ludovico G; Scarcia M; Trombetta C; Claps F; Traunero F; Montanari E; Boeri L; Maggi M; Del Giudice F; Bove P; Forte V; Ficarra V; Rossanese M; Mucciardi G; Pagliarulo V; Tafuri A; Mirone V; Schips L; Antonelli A; Gontero P; Cormio L; Sciarra A; Porpiglia F; Bassi P; Ditonno P; Bostrom PJ; Messina E; Panebianco V; De Cobelli O; Carrieri G
Article: JAMA NETWORK OPEN. 2023;6(9):e2332900
Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy
Falagario UG; Abbadi A; Remmers S; Bjornebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e419
PD15-04 PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e214
MP17-06 VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2023;83:s1613-s1614
Prediction of prostate cancer specific mortality in men undergoing radiotherapy with or without hormonal treatment, risk stratification based on clinical characteristics and PSA treatment response
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2023;83:s379-s380
A0266 Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Article: JAMA ONCOLOGY. 2022;8(7):1019-1026
Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e991
MP58-03 PROSTATE CANCER SCREENING - A NOVEL RISK PREDICTION TOOL WITH STANDARD BIOPSIES VS. PSA WITH MRI-TARGETED BIOPSIES
Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e41
PD03-02 LONG-TERM EFFECTS OF 5Α-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s561-s562
A0362 Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s554-s555
A0358 Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies
Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Article: WORLD JOURNAL OF UROLOGY. 2021;39(6):1797-1804
Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer
Bjornebo L; Olsson H; Nordstrom T; Jaderling F; Gronberg H; Eklund M; Lantz A
Visa fler

Alla övriga publikationer

Thesis / dissertation: 2024
Improving detection and reducing overtreatment of prostate cancer
Björnebo L
Conference publication: EUROPEAN UROLOGY. 2023;83:S379-S380
Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Lantz A; Wiklund P
Letter: JAMA ONCOLOGY. 2022;8(12):1852
Association of 5a-Reductase Inhibitor Use With Prostate Cancer-Specific Mortality-Reply
Bjornebo L; Eklund M; Lantz A
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7844
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
Sanguedolce F; Zanelli M; Palicelli A; Ascani S; Zizzo M; Cocco G; Bjornebo L; Lantz A; Landriscina M; Conteduca V; Falagario UG; Cormio L; Carrieri G
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7819
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression
Sanguedolce F; Zanelli M; Palicelli A; Ascani S; Zizzo M; Cocco G; Bjornebo L; Lantz A; Falagario UG; Cormio L; Carrieri G
Conference publication: EUROPEAN UROLOGY. 2022;81:S561-S562
Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Conference publication: EUROPEAN UROLOGY. 2022;81:S554-S555
Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies
Bjornebo L; Discacciati A; Eklund M; Gronberg H; Lantz A; Nordstrom T
Review: CELL COMMUNICATION AND SIGNALING. 2021;19(1):78
Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease
Archer M; Dogra N; Dovey Z; Ganta T; Jang H-S; Khusid JA; Lantz A; Mihalopoulos M; Stockert JA; Zahalka A; Bjornebo L; Gaglani S; Noh MR; Kaplan SA; Mehrazin R; Badani KK; Wiklund P; Tsao K; Lundon DJ; Mohamed N; Lucien F; Padanilam B; Gupta M; Tewari AK; Kyprianou N

Anställningar

Doktorand, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2020-2024

Examina och utbildning

Läkarexamen, Karolinska Institutet, 2022

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI